D
Dawn Carroll
Researcher at Pfizer
Publications - 55
Citations - 23835
Dawn Carroll is an academic researcher from Pfizer. The author has contributed to research in topics: Analgesic & Placebo. The author has an hindex of 38, co-authored 55 publications receiving 22569 citations. Previous affiliations of Dawn Carroll include University of Oxford & Churchill Hospital.
Papers
More filters
Journal ArticleDOI
Assessing the quality of reports of randomized clinical trials : is blinding necessary?
Alejandro R. Jadad,R. A. Moore,Dawn Carroll,C. Jenkinson,David Reynolds,David J. Gavaghan,Henry J McQuay +6 more
TL;DR: An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
Journal ArticleDOI
A systematic review of antidepressants in neuropathic pain
TL;DR: Antidepressants are effective in relieving neuropathic pain and it is still unclear which drug class should be first choice, with very similar results for anticonvulsants.
Journal ArticleDOI
Anticonvulsant drugs for management of pain: a systematic review.
TL;DR: Systematic review of randomised controlled trials of anticonvulsants for acute, chronic, or cancer pain identified by using Medline, by hand searching, by searching reference lists, and by contacting investigators found anticonVulsants were effective for trigeminal neuralgia and diabetic neuropathy and for migraine prophylaxis.
Journal ArticleDOI
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
Martin R. Tramèr,Dawn Carroll,Fiona Campbell,D John M Reynolds,R Andrew Moore,Henry J McQuay +5 more
TL;DR: The cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness and potentially serious adverse effects, even when taken short term orally or intramuscularly are likely to limit their widespread use.
Journal ArticleDOI
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review
Fiona A Campbell,Martin R. Tramèr,Dawn Carroll,D John M Reynolds,R Andrew Moore,Henry J McQuay +5 more
TL;DR: Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use, and in acute postoperative pain they should not be used.